| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
27,479 |
19,709 |
$1.33M |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
19,373 |
12,667 |
$676K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
8,837 |
6,130 |
$673K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
13,412 |
10,478 |
$624K |
| 99243 |
|
4,989 |
4,120 |
$495K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
9,224 |
7,177 |
$470K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
4,751 |
3,420 |
$372K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
4,748 |
4,002 |
$337K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
3,691 |
2,709 |
$282K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
10,665 |
6,675 |
$246K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
4,714 |
3,539 |
$228K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
4,674 |
3,515 |
$225K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
5,011 |
4,219 |
$218K |
| 99244 |
Office or other outpatient consultation, moderate to high complexity |
885 |
744 |
$129K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
1,641 |
1,174 |
$128K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
4,160 |
3,449 |
$121K |
| 87634 |
|
1,898 |
1,629 |
$98K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
3,102 |
2,237 |
$89K |
| 87481 |
|
1,651 |
1,009 |
$89K |
| 86696 |
|
2,543 |
1,871 |
$70K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
825 |
621 |
$65K |
| 99401 |
|
2,196 |
1,473 |
$64K |
| 87503 |
|
3,543 |
3,033 |
$62K |
| 96160 |
|
4,012 |
3,168 |
$58K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
769 |
562 |
$58K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
2,195 |
1,984 |
$55K |
| 86695 |
|
2,602 |
1,875 |
$55K |
| 99385 |
|
482 |
366 |
$46K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
274 |
268 |
$39K |
| 86803 |
|
2,301 |
1,707 |
$39K |
| 94760 |
|
9,956 |
7,981 |
$38K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,400 |
2,210 |
$37K |
| 87186 |
|
1,713 |
1,291 |
$36K |
| 80053 |
Comprehensive metabolic panel |
3,160 |
2,364 |
$32K |
| 99384 |
|
305 |
286 |
$31K |
| 87510 |
|
1,187 |
812 |
$31K |
| 86704 |
|
1,763 |
1,246 |
$28K |
| 80074 |
|
705 |
584 |
$27K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
193 |
186 |
$27K |
| 86706 |
|
1,801 |
1,268 |
$25K |
| 99383 |
|
266 |
247 |
$25K |
| 96127 |
|
1,675 |
1,445 |
$24K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
226 |
154 |
$22K |
| 87088 |
|
1,989 |
1,539 |
$22K |
| 87563 |
|
535 |
367 |
$22K |
| 87340 |
|
1,580 |
1,163 |
$21K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
2,004 |
1,541 |
$21K |
| 81025 |
|
3,816 |
2,876 |
$19K |
| 81001 |
|
6,239 |
4,639 |
$18K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
3,070 |
2,297 |
$17K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
203 |
179 |
$17K |
| 87070 |
|
2,676 |
2,387 |
$16K |
| G0101 |
Cervical or vaginal cancer screening; pelvic and clinical breast examination |
519 |
356 |
$15K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
604 |
571 |
$15K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,596 |
1,090 |
$15K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
168 |
139 |
$13K |
| 87511 |
|
334 |
268 |
$13K |
| 86592 |
|
2,871 |
2,082 |
$11K |
| 92551 |
|
746 |
629 |
$11K |
| 86705 |
|
599 |
459 |
$9K |
| 94010 |
|
240 |
202 |
$9K |
| 99173 |
|
1,039 |
894 |
$8K |
| 86780 |
|
406 |
323 |
$7K |
| 94060 |
|
127 |
112 |
$6K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
187 |
174 |
$6K |
| 81002 |
|
2,236 |
1,955 |
$6K |
| 87428 |
|
85 |
83 |
$5K |
| 86146 |
|
99 |
77 |
$5K |
| 99070 |
|
572 |
505 |
$4K |
| 87500 |
|
146 |
100 |
$4K |
| 87641 |
|
114 |
88 |
$4K |
| 99382 |
|
43 |
39 |
$4K |
| 87640 |
|
105 |
81 |
$4K |
| 86709 |
|
603 |
458 |
$4K |
| 84443 |
Thyroid stimulating hormone (TSH) |
226 |
181 |
$4K |
| 87581 |
|
89 |
58 |
$3K |
| 81003 |
|
1,165 |
841 |
$3K |
| 86694 |
|
172 |
139 |
$2K |
| 86580 |
|
414 |
352 |
$2K |
| 86769 |
|
27 |
16 |
$2K |
| 87529 |
|
28 |
18 |
$2K |
| 86707 |
|
204 |
142 |
$2K |
| 90715 |
|
85 |
63 |
$2K |
| 87561 |
|
38 |
32 |
$2K |
| 87400 |
|
96 |
95 |
$2K |
| 87807 |
|
159 |
147 |
$2K |
| 84481 |
|
156 |
130 |
$2K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
246 |
211 |
$2K |
| 84439 |
|
151 |
125 |
$1K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
14 |
14 |
$1K |
| 80061 |
Lipid panel |
170 |
135 |
$970.09 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
66 |
57 |
$848.92 |
| 87480 |
|
34 |
25 |
$681.70 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
102 |
77 |
$675.66 |
| 83721 |
|
82 |
66 |
$653.80 |
| 83026 |
|
237 |
213 |
$543.84 |
| 0011A |
|
13 |
13 |
$520.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
391 |
286 |
$502.31 |
| 82728 |
|
52 |
39 |
$372.32 |
| 69210 |
|
17 |
15 |
$363.80 |
| 82962 |
|
182 |
164 |
$329.67 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
36 |
19 |
$328.98 |
| 87081 |
|
55 |
47 |
$319.00 |
| 82947 |
|
85 |
69 |
$305.60 |
| 90658 |
|
29 |
25 |
$303.22 |
| 93000 |
|
13 |
13 |
$287.95 |
| 85018 |
|
116 |
108 |
$269.12 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
17 |
13 |
$150.62 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
73 |
49 |
$99.84 |
| 83690 |
|
13 |
13 |
$87.36 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
132 |
102 |
$19.58 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
22 |
22 |
$0.00 |
| 91301 |
|
27 |
24 |
$0.00 |